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org/licenses/by-nc-nd/4.0/).Abstract Background and aim: Compared to a DASH-type diet, an intensively applied dietary
portfolio reduced diastolic blood pressure at 24 weeks as a secondary outcome in a previous
study. Due to the importance of strategies to reduce blood pressure, we performed an explor-
atory analysis pooling data from intensively and routinely applied portfolio treatments from
the same study to assess the effect over time on systolic, diastolic and mean arterial pressure
(MAP), and the relation to sodium (Naþ), potassium (Kþ), and portfolio components.
Methods and results: 241 participants with hyperlipidemia, from four academic centers across
Canada were randomized and completed either a DASH-type diet (control n Z 82) or a dietary
portfolio that included, soy protein, viscous ﬁbers and nuts (nZ 159) for 24 weeks. Fasting mea-
sures and 7-day food records were obtained at weeks 0, 12 and 24, with 24-h urines at weeks
0 and 24. The dietary portfolio reduced systolic, diastolic and mean arterial blood pressure
compared to the control by 2.1 mm Hg (95% CI, 4.2 to 0.1 mm Hg) (p Z 0.056), 1.8 mm Hg
(CI, 3.2 to 0.4 mmHg) (pZ 0.013) and 1.9 mm Hg (CI, 3.4 to 0.4 mm Hg) (pZ 0.015), respectively.
Blood pressure reductions were small at 12 weeks and only reached signiﬁcance at 24 weeks.
Nuts, soy and viscous ﬁber all related negatively to change in mean arterial pressure (r Z
0.15 to 0.17, p  0.016) as did urinary potassium (r Z 0.25, p Z 0.001), while the Naþ/Kþ
ratio was positively associated (r Z 0.20, p Z 0.010).A1; Apo-B, apolipoprotein B; BMI, body mass index; CHD, coronary heart disease; CHO, carbo-
, C-reactive protein; CVD, cardiovascular disease; DASH, Dietary approaches to stop hypertension;
amingham risk score; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
fatty acids; PUFA, polyunsaturated fatty acids; SBP, systolic blood pressure; SFA, saturated fatty
density lipoprotein cholesterol; TG, triglycerides; waist, waist circumference.
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JENKINS, vegetable protein, blood pressure, and CHD risk 1133Conclusions: Consumption of a cholesterol-lowering dietary portfolio also decreased blood pres-
sure by comparison with a healthy DASH-type diet.
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The DASH (Dietary Approaches to Stop Hypertension) [1]
and OmniHeart [2] diets have reignited [3] interest in
using diet as the treatment for elevated blood pressure and
have been the dietary approaches of choice for both hy-
pertension and cardiovascular disease risk reduction [4].
The dietary portfolio has also been recommended for
cardiovascular disease risk reduction [5e7]. We have
therefore undertaken an exploratory analysis of a previ-
ously published dietary portfolio study that focused on
blood lipid changes and demonstrated a 13e14% reduc-
tion in LDL-C [8]. That study also demonstrated a signif-
icant reduction in diastolic blood pressure on the
intensive portfolio arm as a secondary outcome when
compared to a DASH-type diet. The dietary portfolio
promotes consumption of nuts, soy protein, plant sterols,
and viscous ﬁber to lower serum cholesterol, but of these
dietary components nuts, soy protein, and viscous ﬁber
may also lower blood pressure [9e11]. In the present
analysis we combined the intensively and less intensively
applied dietary portfolio treatments to strengthen the
power of the study. The data for these two treatments
were combined since no signiﬁcant differences were seen
in changes in blood pressure, lipids or dietary compliance
with key ingredients. We have added the 12 week data to
allow the effect over time to be assessed and also added
urinary measures of sodium and potassium, as indicators
of dietary intake that may inﬂuence blood pressure. This
diet was compared with the healthy DASH-type diet as a
positive control.
Methods
This is a secondary analysis of a study with methods
that have been reported previously in detail [8].
The study complies with the Declaration of Helsinki, and
was approved by the ethics committees of St.
Michael’s Hospital and the Universities of Laval, Toronto,
Manitoba, British Columbia and the Natural Health
Products Directorate at Health Canada. Participant writ-
ten informed consent was obtained prior to starting the
study.
Participants
241 participants with hyperlipidemia (93 men and 148
postmenopausal women), >20e85 years, were recruitedfrom 4 centres across Canada. They completed both the
original study and provided 7-day diet histories at the start
and end of the study period (Supplemental Fig. 1) [8].
Those with a history of cancer or a strong family history of
cancer, cardiovascular disease, untreated hypertension
(blood pressure 140/90 mm Hg or greater), diabetes, renal
or liver disease, or currently on lipid lowering medications
were excluded.
Study protocol
In brief, a randomized controlled parallel trial was con-
ducted, involving 3 diets; intensive portfolio (monthly
visits), routine portfolio and control (one 3 month visit for
both), each for a duration of 24 weeks. Blood pressure was
measured at each visit 3 times and the average recorded,
using a digital blood pressure monitor (Omron HEM-
907XL, Omron Healthcare Inc, Vernon Hills, Illinois).
Twenty-four hour urine collections were made at 3 sites at
the start and end of each treatment (n Z 164).
Diets
Participants were counseled at each visit by dietitians to
follow weight maintaining vegetarian diets during the 6
month study period. Each participant was given a 7 day
study food checklist to follow [8]. For both the intensive and
routine dietary portfolio the recommended targets were:
9.8 g of viscous ﬁbers per 1000 kcal diet, from barley, oats,
psyllium, eggplant, and okra; 22.5 g of soy protein per
1000 kcal, from components of soy milk, tofu and soy meat
analogs; 22.5 g of nuts per 1000 kcal; and 0.94 g of plant
sterols per 1000 kcal from a margarine enriched with plant
sterol esters [8]. The control dietary intervention empha-
sized avoidance of the speciﬁed core portfolio dietary
components above and recommended a lacto-ovo-
vegetarian DASH-type diet that focused on low saturated
fat, whole grain cereals with low fat dairy, fruit and vege-
tables, and a reduction in red meat and snack foods [12].
Adherencewith the dietary interventions was estimated
as mean daily intakes from 7-day diet histories. For the
dietary portfolio adherencewas assessed based on servings
of soy protein foods, nuts, viscous ﬁber foods, and plant
sterol margarine consumed, with each contributing 25%
when taken at the recommended amount (Supplemental
Table 1a). For the DASH-type diet, increased servings of
fruit, vegetables and low fat dairy contributed positively to
the score and servings of red meat and snack foods
1134 D.J.A. Jenkins et al.consumed contributed negatively to the score. The number
of servings, expressed as a percentage (one serving Z
7.75%) were used to assess adherence based on the average
DASH servings of fruit, vegetables and low fat dairy,
providing a total of 12.9 servings per 2000 kcal diet (100%
adherence) as recommended in a recent publication
(Supplemental Table 1b) [12].
Analyses
Blood samples were analyzed in each centre’s hospital or
routine laboratory, and diets were analyzed using a pro-
gram based on the US Department of Agriculture data [8].
Statistical analysis
The results are expressed as means [95% conﬁdence in-
terval (CI)]. No signiﬁcant differences were observed in the
original report between the intensive and routine treat-
ments in terms of dietary compliance, or changes in body
weight, blood lipids or blood pressure [8]. Therefore the
two dietary portfolios were considered here as a single
treatment with 241 participants completing the study. The
primary outcome was change in mean arterial pressure
from baseline to week 24 in the completers. This measure
combines systolic and diastolic blood pressure in the ratio
1 SBP: 2 DBP. A repeated measures mixed-effects model,
using compound symmetry covariance (PROC MIXED, SAS
version 9.4), was used to estimate least squares mean
within and between-treatment changes for all variables.
The results are presented both with and without adjust-
ment for changes in covariates including waist, BMI, age,
sex, blood pressure medication and baseline values. C-
reactive protein (CRP) values were log transformed to
satisfy distributional assumptions. A sensitivity analysis
was conducted using generalized estimating equations
(PROC GENMOD) with an exchangeable correlation struc-
ture to validate the ﬁndings obtained from the
mixed-effects model. The mixed models were also run
excluding participants on blood pressure medications, as
well as using all participants providing at least one post-
randomization measure (intention-to-treat).
Complete dietary data were only available for week
0 and week 24. Change in dietary variables was expressed
as percent kilocalories for macronutrients and milligrams/
1000 kilocalories for micronutrients. Both baseline and
change values of the three active dietary components
assessed were found to be non-normally distributed
(ShapiroeWilk p < 0.005), as a large number of partici-
pants were consuming none of the components at baseline
(nuts n Z 39, soy protein foods n Z 128, viscous ﬁber
foods n Z 34). Therefore, Spearman correlations (PROC
CORR) were used to assess the relation between the di-
etary intake data and changes in blood pressure using the
data from all the treatments. Urinary data were treated
similarly.
The Framingham coronary heart disease and cardio-
vascular risk factor scores (FRS) were calculated using the
variables of age, sex, systolic blood pressure, totalcholesterol and HDL-C. The exclusion criteria accounted
for diabetes status [13].
Results
Dietary adherence, in terms of desired number of servings,
was 48% on the dietary portfolio and 105% on the DASH-
type control (Supplemental Table 1aeb) at week 24. A
relative increase in fat intake was observed on the port-
folio compared to the DASH-type control by 8% of total
calories with a corresponding reduction in available car-
bohydrate (p < 0.0001), and related to increased nut
intake. No change was seen in total protein intake, but a
30% (95% CI, 26e34%) (p < 0.0001) relative increase in
vegetable protein as a proportion of total protein was
observed in the portfolio group. Sodium intake remained
constant but potassium was signiﬁcantly higher on the
control diet by 127 mg/d (CI, 242 to 12 mg/d)
(pZ 0.031). No difference was seen between the portfolio
and control treatments in the change in body weight, BMI,
or waist circumference (Table 1).
Blood pressure
There was no signiﬁcant difference in the number of
people taking blood pressure medications by treatment
(Fisher’s exact test, pZ 0.235). In the portfolio and control
diet groups, 28 (18%) and 20 (24%) participants, respec-
tively, were taking blood pressure medications. No
changes were observed in use of blood pressure medica-
tions throughout the study. Using completer data from 12
to 24 weeks in the unadjusted model for the primary
analysis; systolic, diastolic, and mean arterial pressure
were reduced on the portfolio diet by 2.5 mm Hg (CI, 3.7 to
1.2 mm Hg) (p < 0.001), 2.0 mm Hg (CI, 2.8 to 1.2 mm Hg)
(p < 0.001), and 2.1 mm Hg (CI, 3.0 to 1.3 mm Hg)
(p < 0.001), respectively, (Fig. 1) with no signiﬁcant
changes on the control diet, resulting in relative reductions
in blood pressure on the dietary portfolio: systolic
2.1 mm Hg (CI, 4.2 to 0.1 mm Hg) (p Z 0.056); diastolic,
1.8 mm Hg (CI, 3.2 to 0.4 mm Hg) (p Z 0.013); and mean
arterial pressure, 1.9 mm Hg (CI, 3.4 to 0.4 mm Hg)
(p Z 0.015) (Table 1). A sensitivity analysis using gener-
alized estimating equations for the reduction in systolic
blood pressure values were signiﬁcant at 2.1 mm Hg (CI,
4.1 to 0.1 mm Hg) (p Z 0.040).
After including baseline, waist circumference, BMI, age,
sex, and blood pressure medication as covariates in the
repeated measures (weeks 12 and 24) model, the signiﬁ-
cance of relative reductions were maintained (Table 1).
Using all available data from the original study partic-
ipants (n Z 345) showed similar treatment differences
and signiﬁcance levels to those reported for the completer
data. The fully adjusted model showed reductions in sys-
tolic blood pressure, 1.3 mm Hg (CI, 2.5 to 0.2) p Z 0.025,
diastolic blood pressure, 0.9 mm Hg (CI, 1.7 to 0.2)
pZ 0.015, and mean arterial pressure 1.1 mm Hg (CI, 1.9 to
0.3) p Z 0.01. Similarly, elimination of those on blood
pressure medications also conﬁrmed these treatment
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Figure 1 Changes in systolic (A), diastolic (B), and mean arterial
pressure (MAP) (C) in portfolio and control diets at weeks 0, 12, and 24.
* represents signiﬁcance at P<0.05.
JENKINS, vegetable protein, blood pressure, and CHD risk 1135differences in blood pressure (reductions in systolic blood
pressure, 2.6 mm Hg, (CI, 4.7 to 0.5) p Z 0.009, diastolic
blood pressure, 1.5 mm Hg, (CI, 2.9 to 0.2) pZ 0.027, mean
arterial pressure 1.9 mm Hg (CI, 3.3 to 0.5) p Z 0.009).
Framingham cardiovascular risk score
A corresponding relative reduction was seen on the port-
folio in 10-year cardiovascular risk scores for both coro-
nary heart disease and cardiovascular disease 1.2% (CI, 1.7
to 0.7%, p < 0.001) and 1.4% (CI, 2.0 to 0.8%, p < 0.001)
respectively. This risk reduction was in turn contributed to
by the relative reduction in total cholesterol of 0.7 mmol/L
(CI, 0.9 to 0.5 mmol/L) (p < 0.001) on the portfolio with no
change in HDL-C. There were also corresponding re-
ductions in both apolipoprotein-B [0.2 g/L (CI, 0.2 to 0.1 g/
L), p < 0.001] and log CRP concentrations [0.3 mg/L (CI, 0.4
1136 D.J.A. Jenkins et al.to 0.1 mg/L), log CRP p Z 0.007] (Table 1). The servings of
dietary portfolio foods were also related to reductions in
CHD and CVD risk (Table 2).
Key components of the dietary portfolio compared to
DASH-type control
On the dietary portfolio treatment differences included
relative increases in intake of nuts [17 g/1000 kcal/d (CI,
15e20 g/1000 kcal/d)], soy protein [3.4% (CI, 2.8e3.9%)
equivalent to 13.6 g/1000 kcal/d], and viscous ﬁbers [4.6 g/
1000 kcal (CI, 3.8e5.3 g/1000 kcal)] compared to the
control group (Supplemental Table 3).
Using spearman correlations, and pooling test and
control treatments, change in dietary portfolio adherence
was related signiﬁcantly to change in diastolic (rZ 0.18,
p Z 0.006) and mean arterial pressure (r Z 0.16,
p Z 0.011). No signiﬁcant associations were seen with
DASH adherence. Change in all three key dietary portfolio
components were also signiﬁcantly related to reductions
in mean arterial pressure: nuts (rZ 0.15, pZ 0.016), soy
(r Z 0.16, p Z 0.015), and viscous ﬁber (r Z 0.17,
pZ 0.009), similar associations were seen for systolic and
diastolic blood pressures (Table 2). Among participants on
the DASH-type control diet, no signiﬁcant correlations
were seen between portfolio adherence and blood pres-
sure outcomes; however, DASH adherence showed signif-
icant negative correlations with systolic (r Z 0.35,
P Z 0.001), diastolic (r Z 0.24, P Z 0.033) and mean
arterial pressure (r Z 0.30, P Z 0.005). No associations
were seen between adherence to either diet and blood
pressure amongst participants on the dietary portfolio diet
(Supplemental Table 4).Table 2 Change in dietary variables versus change in blood pressure, CH
Dietary variable Systolic blood
pressure (SBP)
Diastolic blood
pressure (DBP)
Mea
pres
r p-value r p-value r
Total calories (kcal) 0.04 0.56 0.04 0.54 0.0
Protein (%) 0.09 0.19 0.02 0.79 0.0
Soy protein (%) 0.09 0.15 0.19 0.003 0.1
Fat (%) 0.07 0.28 0.10 0.14 0.0
SFA (%) 0.10 0.11 0.12 0.07 0.12
MUFA (%) 0.13 0.038 0.14 0.025 0.1
PUFA (%) 0.14 0.030 0.18 0.006 0.1
Cholesterol (mg/1000 kcal) 0.04 0.58 0.11 0.10 0.08
Alcohol (%) 0.02 0.81 0.07 0.31 0.04
Net CHO (%) 0.10 0.11 0.08 0.24 0.10
Total ﬁber (g/1000 kcal) 0.08 0.23 0.15 0.016 0.1
Viscous ﬁber (g/1000 kcal) 0.14 0.034 0.17 0.010 0.1
Nuts (g/1000 kcal) 0.11 0.09 0.16 0.011 0.1
Plant sterols (g/1000 kcal) 0.06 0.39 0.12 0.07 0.1
Naþ (mg/1000 kcal) 0.05 0.45 0.09 0.18 0.08
Kþ (mg/1000 kcal) 0.10 0.13 0.03 0.61 0.07
Naþ/Kþ 0.14 0.032 0.10 0.14 0.12
Portfolio
Adherence 0.11 0.08 0.18 0.006 0.1
DASH
Adherence 0.08 0.24 0.03 0.66 0.0
Data presented are Spearman correlations. Bold values indicate statisticalDietary Naþ, Kþ, and Naþ/Kþ ratio
Treatment differences included a relative reduction in di-
etary potassium on the portfolio due to an absolute in-
crease in dietary potassium intake on the control diet
[127 mg/1000 kcals (CI, 242 to 12 mg/1000 kcals),
p Z 0.031] with no changes in dietary sodium. Further
there was no association between the change in dietary
potassium, sodium, or the sodium to potassium ratio with
any blood pressure measure. However baseline dietary
potassium and the Naþ/Kþ ratios, but not sodium, were
signiﬁcantly related to baseline mean arterial pressure
(r Z 0.19, n Z 241, p Z 0.004, and r Z 0.19, n Z 241,
pZ 0.004; and rZ 0.08, nZ 241, pZ 0.195) respectively.
Similar associations were seen for systolic and diastolic
blood pressure.
Urine Naþ and Kþ: relation to diet and blood pressure
Creatinine adjusted urinary potassium output increased on
the DASH-type control relative to the portfolio [0.9 (CI 1.6
to 0.2) p Z 0.016] in keeping with the dietary increase
(Supplementary Table 3). As anticipated urinary measures
were signiﬁcantly correlated with dietary measures: so-
dium (baseline r Z 0.29, p < 0.001), potassium (baseline
r Z 0.42, week 24 r Z 0.45, and change r Z 0.33, all
p < 0.001), as well as dietary protein intake compared to
urinary urea output (baseline r Z 0.27, p < 0.001, and
change r Z 0.17 p Z 0.028).
However unlike the dietary measures, urinary changes
in potassium correlated inversely with changes in systolic
(r Z 0.25, p Z 0.001), diastolic (r Z 0.23, p Z 0.004),
and mean arterial pressure (r Z 0.25, pZ 0.001); whileD, and CVD risk.
n arterial
sure (MAP)
Coronary heart disease
(CHD) risk
Cardiovascular disease
(CVD) risk
p-value r p-value r p-value
1 0.94 0.04 0.51 0.02 0.81
3 0.67 0.08 0.24 0.06 0.36
6 0.015 0.31 <0.0001 0.31 <0.0001
9 0.15 0.25 0.000 0.22 0.001
0.06 0.16 0.014 0.18 0.005
5 0.017 0.27 <0.0001 0.26 <0.0001
8 0.006 0.30 <0.0001 0.30 <0.0001
0.24 0.14 0.026 0.16 0.012
0.52 0.01 0.88 0.00 0.99
0.11 0.27 <0.0001 0.25 <0.0001
3 0.045 0.19 0.004 0.21 0.001
7 0.009 0.33 <0.0001 0.35 <0.0001
5 0.016 0.31 <0.0001 0.31 <0.0001
1 0.10 0.21 0.001 0.24 0.000
0.22 0.08 0.22 0.09 0.16
0.31 0.04 0.58 0.04 0.58
0.06 0.06 0.36 0.11 0.09
6 0.011 0.32 <0.0001 0.34 <0.0001
5 0.44 0.09 0.16 0.05 0.46
signiﬁcance.
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(r Z 0.21, p Z 0.007), diastolic (r Z 0.17, p Z 0.026), and
mean arterial pressure (r Z 0.20, p Z 0.010). Changes in
urinary sodium did not relate to changes in blood pressure,
possibly due to the lack of signiﬁcant change in dietary
sodium intake and urinary sodium output.
Discussion
This exploratory analysis indicated that consumption of
the dietary portfolio lowers blood pressure when
compared with a healthy DASH-type diet emphasizing low
fat dairy, fruit and vegetables, whole grains, reduced meat
intake and elimination of snack foods. The modest effect at
2 mm Hg was therefore in addition to what would be
expected from DASH-type diets that have produced
10 mm Hg blood pressure reductions in study participants
with an initial mean systolic blood pressure of 130 mm Hg
[12]. This blood pressure reduction, combined with the
effect of the dietary portfolio in the blood lipid proﬁle,
resulted in a signiﬁcant reduction in the cardiovascular
disease risk score. Despite excellent compliance of over
100%, the DASH-type diet nevertheless failed to reduce
blood pressure probably because the baseline therapeutic
diet of the participants already had many of the DASH diet
features (already over 60% compliance) and blood pressure
was already low at 119/73 mm Hg. Nevertheless increased
compliance to the DASH diet components on the control
was still associated with reduced blood pressure.
For cardiovascular risk reduction, the Canadian Car-
diovascular Society has promoted use of the DASH and
Mediterranean diets, as well as the dietary portfolio, also
recommended for statin intolerance by the European
Atherosclerosis Society, based on its cholesterol lowering
potential. The American Heart Association/American Col-
lege of Cardiology guidelines recommend the DASH diet
[6,7,14]. The present study demonstrates a blood pressure
advantage of increasing vegetable fat and protein, in
keeping with blood pressure and cardiovascular advan-
tages from other studies [12,15].
Consumption of 30 g of mixed nuts (walnuts, almonds
and hazelnuts) as part of a Mediterranean diet was asso-
ciated with a signiﬁcant 0.65 mm Hg reduction in diastolic
blood pressure possibly related to the monounsaturated
fat content [16]. The mean nut intake in the present study
was w36 g/d. Similarly soy protein has been shown in a
number of studies and through a meta-analysis to lower
blood pressure [10,17]. Viscous ﬁber intake has also been
associated with blood pressure reduction [18]. Soluble
ﬁber from fruit and vegetable intake reduced coronary
heart disease risk [19], with strong data for cereal ﬁber
that in some but not all studies reduced cardiovascular risk
factors [20].
There is uncertainty over the ideal level of salt reduc-
tion [1,21e26]. Our data pose the question of whether
foods that have both blood pressure and lipid lowering
properties could be permitted to contain more salt to
improve palatability than less cardiovascular protective
foods. Thus, the present dietary portfolio that reducedsystolic blood pressure by 2.5 mm Hg across the dietary
period, also reduced total-cholesterol:HDL-C by 10e11%
providing a reduction in CVD Framingham risk score of
1.6% per 10 years. Addition of an extra 500 mg of sodium to
that diet would be predicted to increase systolic blood
pressure by only 1.22 mm Hg [1] but would lessen the
reduction in the FRS by only 0.2% still leaving a beneﬁt of
1.4% reduced CVD risk per 10 years.
The study weakness includes the fact that blood pres-
sure was not the primary outcome; the present analysis
was therefore a secondary, exploratory analysis with all
the limitations that post hoc analyses involve. 24-hour
ambulatory blood pressure may have provided a better
reﬂection of the effect of the dietary interventions [27]. In
addition baseline blood pressure was low at 119/73 mm Hg
making further reductions difﬁcult and thus likely under-
estimating the true blood pressure lowering effect [1].
Good adherence to a DASH-type diet at baseline (65e68%)
further limited demonstration of blood pressure lowering
of both portfolio and DASH-type control treatments and
illustrated the ease of compliance with the DASH diet. The
dietary portfolio was only complied with by 48%, which
limits the effect that could potentially be expected.
Nevertheless, 14% LDL-C reduction was still observed at
this compliance level [8] compared to the 30% LDL-C
reduction seen when all portfolio foods were provided
under metabolic conditions [28]. The colinearity of the
active ingredients by the design of the diets made it
difﬁcult to undertake multiple regression. The sodium ef-
fect could have been explored with two levels of sodium
intake as was demonstrated in the DASH diet [1].
The strength of the study was the demonstration in
centres across the continent that healthy food components
may create diets that address many risks factors, including
blood pressure, blood lipids, and inﬂammatory biomarkers
as part of a broad based cardiovascular disease risk
reduction strategy.
We conclude that a dietary portfolio emphasizing
cholesterol lowering foods also reduces blood pressure.
Overall, plant based diets, notably the PREDIMED diet,
emphasizing foods higher in protein, oil, and ﬁber have
been associated with reduced cardiovascular disease and
stroke [15,29]. A recent meta-analysis of vegetarian diets
also demonstrated a reduction in blood pressure [30]
further supporting the use of plant foods for the reduc-
tion of blood pressure. Future studies could usefully
compare the effects of the dietary portfolio with the DASH
diet in moderately hypertensive participants with blood
pressure as the primary outcome.
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